Talphera, Inc. (TLPH)
After hours:
| Previous Close | 0.9911 |
| Open | 1.0106 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.0000 - 1.0400 |
| 52 Week Range | 0.4300 - 1.6100 |
| Volume | |
| Avg. Volume | 96,904 |
| Market Cap | 17.673M |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.42 |
PR NewswireTalphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2024 financial results after market close on Tuesday, May 14, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the results and provide an update on the Company's business.
- PR Newswire
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter 2023 financial results and provided a corporate update.
- PR Newswire
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced as part of its commitment to operating with best practices in corporate governance, its Board of Directors has decided to reduce the size of the Board from ten to seven directors. Three directors, Howard Rosen, Richard Afable and Pamela Palmer have voluntarily agreed to resign from the Boar
